Buprenorphine/naloxone - one formulation that doesn't fit all: a case report
Abstract Background Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when sublingual (SL) buprenorphine/naloxone is taken as prescribed; it is thought to...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Buch |
Veröffentlicht: |
BMC,
2024-07-01T00:00:00Z.
|
Schlagworte: | |
Online-Zugang: | Connect to this object online. |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Online
Connect to this object online.3rd Floor Main Library
Signatur: |
A1234.567 |
---|---|
Exemplar 1 | Verfügbar |